Petros Grivas, MD, shares his treatment plan for a patient with metastatic urothelial cancer who has progressed following platinum-based chemotherapy.

Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.

Staying Up To Date On Treatment of Myelofibrosis With John Mascarenhas, MD

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Ilaria Betella and Francesco Multinu. Dr. Betella is an attending in the Department of Gynecologic Surgery at the European Institute of Oncology (IEO) in Milan. Her research focuses on molecular classification of endometrial cancer and on hereditary gynecologic cancer syndromes. Dr. Multinu is a gynecologic oncologist at the European Institute of Oncology (IEO) in Milan as well as a research collaborator in the Department of Obstetrics and Gynecology, Division of Gynecologic Surgery at the Mayo Clinic in Rochester, Minnesota. His special research interests include surgical and postoperative treatment of endometrial cancer.

Highlights:

- There is evidence that the new molecular classification will be the future in the management of endometrial cancer.

- The implementation of molecular analysis allows oncologists to reallocate to a different risk class 6.8% of endometrial cancers that otherwise would have been misclassified and consequently undertreated or overtreated.

- The interpretation of molecular classification requires a validated hierarchical algorithm, for which POLE analysis is essential: Even though POLE testing has not been implemented in many institutions, there is no way to use part of the molecular analysis and completely escape POLE analysis.

- According to the new algorithm proposed by Dr. Betella et al., POLE analysis could be spared in 67% of patients and reserved only for those in whom the incorporation of the molecular classification could change the risk class attribution and post-operative management.

Molecular Classification of Endometrial Cancer with Drs. Ilaria Betella and Francesco Multinu

Applied Physics for Radiation Oncology eBook PDF

Download Link ==>> https://royalworlduslibsnew993.blogspot.com/1930524404

Download Applied Physics for Radiation Oncology PDF - KINDLE - EPUB - MOBI
Applied Physics for Radiation Oncology download eBook PDF EPUB

Download Applied Physics for Radiation Oncology read ebook Online PDF EPUB KINDLE
Applied Physics for Radiation Oncology pdf download
Applied Physics for Radiation Oncology read online
Applied Physics for Radiation Oncology epub
Applied Physics for Radiation Oncology vk
Applied Physics for Radiation Oncology amazon
Applied Physics for Radiation Oncology free download pdf
Applied Physics for Radiation Oncology pdf free
Applied Physics for Radiation Oncology epub download
Applied Physics for Radiation Oncology mobi
Download Applied Physics for Radiation Oncology PDF - KINDLE - EPUB - MOBI
Applied Physics for Radiation Oncology download eBook PDF EPUB
[DOWNLOAD] Applied Physics for Radiation Oncology in format PDF
Applied Physics for Radiation Oncology download book in format PDF


#downloadbook #book #readonline #readbookonline #ebookcollection #ebookdownload #pdf #ebook #epub #kindle

Books⚡️Download❤️ Applied Physics for Radiation Oncology Ebooks

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Félix Boria to discuss the validation of ESGO quality indicators for cervical cancer. Mr. Boria is an attending physician of the gynecologic oncology division at the University of Navarra (Madrid, Spain) under the mentorship of Dr. Luis Chiva. He is currently finishing his PhD at Universidad Autonoma de Madrid about PET/CT and advanced ovarian cancer.

Highlights:

- Women who were operated on centers with high compliance of quality indicators had significant lower risk of relapse (HR, 0.39; 95% CI, 0.25 to 0.61; p<0.001). The association remained significant after further adjustment for conization, surgical approach and use of manipulator and for adjuvant therapy.

- High compliance centers performed more open surgeries (58.4% vs 36.7%, p<0.01), more cone biopsies (45.4% vs 30.0%, p<0.01), lower use of a uterine manipulator (15.5% vs 31.7%, p<0.01), lower use of adjuvant treatment (40.2% vs 48.4%, p=0.01).

- The rate of adjuvant treatment in Europe is surprisingly high, especially in low compliance centers (48%). Future investigations should try to address if we are overtreating patients with cervical cancer.

SUCCOR: Validation of ESGO Quality Indicators Cervical Cancer with Félix Boria

`Read or Download EPUB Clinical Trials in Oncology, Third Edition (Chapman & Hall/CRC Interdisciplinary Statistics) by Stephanie Green,Jacqueline Benedetti on Iphone Full Pages. Here=> https://rz.freereadpdf.club/?book=1138199117 <=.Supporting format: PDF, EPUB, Kindle, Audio, MOBI, HTML, RTF, TXT, etc.
download or read ePub/pdf Clinical Trials in Oncology, Third Edition (Chapman & Hall/CRC Interdisciplinary Statistics) Kindle Unlimited by Stephanie Green,Jacqueline Benedetti [Author] PDF is a great book to read and that's why I recommend reading Clinical Trials in Oncology, Third Edition (Chapman & Hall/CRC Interdisciplinary Statistics) on Textbook.
#download #book #read #readbook #ebook #audiobook #pdf #ebook #epub #kindle

Read* Clinical Trials in Oncology, Third Edition Chapman & Hall/CRC Interdisciplinary Statistics

Synopsis: 

Bill Hinshaw is the President and CEO of Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. Bill entered biotech a little over four years ago following a long life sciences career in pharma, working for companies such as Novartis and Schering Plough. He joins host Rahul Chaturverdi for a discussion about where Axcella is from a development perspective and the therapeutic areas they’re pursuing, the company’s work to treat long Covid, the challenges of developing drugs to treat nonalcoholic steatohepatitis (NASH), and Axcella’s “combination by design” multi-targeted approach to tackle complex diseases.


Read More on Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) https://bit.ly/3U0iEa6

Biography: 
Mr. Hinshaw joined Axcella as CEO in May 2018. He is the former Executive Vice President of U.S. Oncology at Novartis Pharmaceuticals Corporation, having served 15 years with the organization. Mr. Hinshaw led all aspects of this >$6B organization, heading up more than a dozen product launches, including Tasigna®, Gleevec®, and Kymriah®; the integration of the GSK oncology portfolio; innovative medical, commercial, and market access models; and a patient-centric focus on education and support programs.  He also played a key role on the Global Oncology Executive Committee, including leading key strategic programs to maximize the portfolio and pipeline development.

Mr. Hinshaw was formerly the Head of the Northern and Central Europe Region for Novartis Oncology where he was responsible for leading all functions across 33 countries. Prior to that role, Mr. Hinshaw was the head of Group Emerging Markets, which included all divisions of Novartis in 50 countries worldwide.

Prior to his role as EVP, Mr. Hinshaw held a number of lead roles for Novartis, including Head of the Hematology Business Franchise, which achieved >20% overall growth each year under Mr. Hinshaw’s leadership. He also was the Global Head of Infectious Disease and Transplantation and Immunology (IDTI) based out of Basel, Switzerland, with responsibility for all functions of the organization, including commercial, development, BD&L, and strategy for the Business Unit. Other Novartis positions held by Mr. Hinshaw included Global Head of Infectious Disease Marketing and IDTI Development and Business Development & Licensing; Business Franchise Head, Infectious Disease; and Head of Infectious Disease Marketing.

Mr. Hinshaw started his career at Schering Plough, where over the course of 12 years, he held a series of roles of increasing responsibility in the sales and marketing functions in both primary care and specialty business units, including market research, new products and in-line brand management, and sales positions at the representative, district, regional, and national levels. He also led the U.S. Oncology Unit where he was responsible for sales, marketing and business development.

Mr. Hinshaw holds a B.S. in Molecular Biology from the University of Wisconsin.

129. Progress in complex diseases: NASH, Long COVID, and beyond, Bill Hinshaw, Pres. & CEO, Axcella

The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) eBook PDF

Download Link ==>> https://royalworlduslibsnew993.blogspot.com/1608312844

Download The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) PDF - KINDLE - EPUB - MOBI
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) download eBook PDF EPUB

Download The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) read ebook Online PDF EPUB KINDLE
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) pdf download
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) read online
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) epub
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) vk
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) amazon
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) free download pdf
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) pdf free
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) epub download
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) mobi
Download The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) PDF - KINDLE - EPUB - MOBI
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) download eBook PDF EPUB
[DOWNLOAD] The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) in format PDF
The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) download book in format PDF


#downloadbook #book #readonline #readbookonline #ebookcollection #ebookdownload #pdf #ebook #epub #kindle

E.B.O.O.K.✔️ The MD Anderson Surgical Oncology Handbook (Lippincott Williams & Wilkins Handbook) Ful

Brothers Rakesh Popat, PhD, multiple myeloma expert, and Sanjay Popat, PhD, thoracic oncologist, join the show for a special discourse on surrogate endpoints and patient benefit. The conversation fluctuates between the “assumption” that surrogate endpoints translate to better survival; breakdowns of the utility and association with overall survival of PFS, ORR, and MRD in the latest literature; reimbursement intricacies and issues surrounding surrogate endpoint criteria; and the need for stronger confirmatory trials after accelerated approvals, along with plenty more important points for consideration.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Surrogate Endpoints in Solid and Liquid Tumors

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Soo Park, Assistant Professor in the Division of Hematology-Oncology at UC San Diego Health. Together they discuss how precision medicine and molecular profiling have shaped the way we care for patients with cutaneous cancers.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. Soo Park: Cutaneous Oncology and Precision Medicine

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

Healthcare Unfiltered is an honest, raw, timely podcast tackling any and all topics in healthcare that affect stakeholders. Dr. Chadi Nabhan uses his dynamic conversational skills to challenge his guests to address controversial and important topics. He also brings on world renowned experts to discuss clinical advances in medicine.

New tracks tagged #oncology